ELVN
Enliven Therapeutics Inc.
NASDAQ: ELVN · HEALTHCARE · BIOTECHNOLOGY
$54.32
-3.40% today
Updated 2026-09-11
Market cap
$4.35B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.65
Dividend yield
—
52W range
$15 – $62
Volume
0.9M
WallStSmart proprietary scores
27
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C8.5
Quality
A3.0
Profitability
D5.0
Valuation
C+3/9
Piotroski F-Score
Weak
16.0
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →251 stocks currently score above 75
Price targets
Analyst target
$73.90
+36.05%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy10 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 15.95 — safe zone
+ Debt/equity 0.00x — low leverage
Risks
- Piotroski 3/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-18.63M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-37.66M | $-71.58M | $-89.02M | $-103.69M | $-32.48M |
| EPS | — | — | — | — | $-1.65 |
| Free cash flow | $-32.69M | $-61.42M | $-73.24M | $-70.46M | $-18.63M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Enliven Therapeutics Inc. trades at $54.32. Our Smart Value Score of 27/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 15.95, it sits in the safe zone.
Frequently asked questions
What is Enliven Therapeutics Inc.'s stock price?
Enliven Therapeutics Inc. (ELVN) trades at $54.32.
Is Enliven Therapeutics Inc. overvalued?
Enliven Therapeutics Inc. carries a Smart Value Score of 27/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Enliven Therapeutics Inc. (ELVN)?
The 12-month analyst consensus target is $73.90, about 36.0% above the current $54.32. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Enliven Therapeutics Inc.'s Altman Z-Score is 15.95, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-21.79%
Beta0.25
50D MA$55.67
200D MA$37.63
Shares out0.07B
Float0.06B
Short ratio—
Avg volume0.9M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—